Research and Development Expense of Keenova Therapeutics plc from 30 Sep 2011 to 26 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
Summary
Keenova Therapeutics plc quarterly and annual Research and Development Expense in USD history and change rate from 30 Sep 2011 to 26 Sep 2025.
  • Keenova Therapeutics plc Research and Development Expense for the quarter ending 26 Sep 2025 was $44,300,000, a 57% increase year-over-year.
  • Keenova Therapeutics plc Research and Development Expense for the twelve months ending 26 Sep 2025 was $118,800,000, a 17% increase year-over-year.
  • Keenova Therapeutics plc annual Research and Development Expense for 2024 was $115,700,000.
  • Keenova Therapeutics plc annual Research and Development Expense for 2021 was $205,200,000, a 29% decline from 2020.
  • Keenova Therapeutics plc annual Research and Development Expense for 2020 was $290,800,000, a 17% decline from 2019.
Source SEC data
View on sec.gov
Research and Development Expense, Trailing 12 Months (USD)
Research and Development Expense, Quarterly (USD)
Research and Development Expense, YoY Quarterly Change (%)
Research and Development Expense, Annual (USD)
Research and Development Expense, YoY Annual Change (%)

Keenova Therapeutics plc Quarterly Research and Development Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $118,800,000 $44,300,000 +$16,100,000 +57% 28 Jun 2025 26 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $102,700,000 $23,600,000 -$5,600,000 -19% 29 Mar 2025 27 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $108,300,000 $20,500,000 -$7,400,000 -27% 28 Dec 2024 28 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $115,700,000 $30,400,000 +$14,500,000 +91% 28 Sep 2024 27 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $101,200,000 $28,200,000 +$2,500,000 +9.7% 29 Jun 2024 27 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $98,700,000 $29,200,000 +$200,000 +0.69% 30 Mar 2024 28 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $98,500,000 $27,900,000 -$400,000 -1.4% 30 Dec 2023 29 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $15,900,000 15 Nov 2023 29 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $25,700,000 -$2,600,000 -9.2% 01 Jul 2023 29 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $29,000,000 +$22,800,000 +368% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $28,300,000 -$8,900,000 -24% 31 Dec 2022 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $110,600,000 $28,300,000 -$19,000,000 -40% 02 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $6,200,000 -$46,600,000 -88% 17 Jun 2022 01 Jul 2022 10-Q 09 Aug 2023 2023 Q2
Q2 2022 $129,600,000 $28,300,000 -$24,500,000 -46% 02 Apr 2022 16 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $176,200,000 $37,200,000 -$29,000,000 -44% 01 Jan 2022 01 Apr 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $205,200,000 $38,900,000 -$26,100,000 -40% 25 Sep 2021 31 Dec 2021 10-K 26 Mar 2024 2023 FY
Q3 2021 $231,300,000 $47,300,000 -$18,200,000 -28% 26 Jun 2021 24 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $249,500,000 $52,800,000 -$30,100,000 -36% 27 Mar 2021 25 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $279,600,000 $66,200,000 -$11,200,000 -14% 26 Dec 2020 26 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $290,800,000 $65,000,000 -$16,400,000 -20% 26 Sep 2020 25 Dec 2020 10-K 03 Mar 2023 2022 FY
Q3 2020 $307,200,000 $65,500,000 -$37,600,000 -36% 27 Jun 2020 25 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $344,800,000 $82,900,000 +$3,300,000 +4.1% 28 Mar 2020 26 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $341,500,000 $77,400,000 -$7,900,000 -9.3% 28 Dec 2019 27 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $349,400,000 $81,400,000 -$19,000,000 -19% 28 Sep 2019 27 Dec 2019 10-K 15 Mar 2022 2021 FY
Q3 2019 $368,400,000 $103,100,000 +$17,000,000 +20% 29 Jun 2019 27 Sep 2019 10-Q 03 Nov 2020 2020 Q2
Q2 2019 $351,400,000 $79,600,000 -$13,000,000 -14% 30 Mar 2019 28 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $364,400,000 $85,300,000 +$3,300,000 +4% 29 Dec 2018 29 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $361,100,000 $100,400,000 -$32,300,000 -24% 29 Sep 2018 28 Dec 2018 10-K 10 Mar 2021 2020 FY
Q3 2018 $393,400,000 $86,100,000 +$39,200,000 +84% 30 Jun 2018 28 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $354,200,000 $92,600,000 +$40,300,000 +77% 31 Mar 2018 29 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $313,900,000 $82,000,000 +$37,000,000 +82% 30 Dec 2017 30 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $276,900,000 $132,700,000 +$66,600,000 +101% 30 Sep 2017 29 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $210,300,000 $46,900,000 -$21,000,000 -31% 01 Jul 2017 29 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $231,300,000 $52,300,000 -$22,500,000 -30% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $253,800,000 $45,000,000 -$13,100,000 -23% 31 Dec 2016 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $266,900,000 $66,100,000 +$4,800,000 +7.8% 01 Oct 2016 30 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 $262,100,000 $67,900,000 +$35,200,000 +108% 25 Jun 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $226,900,000 $74,800,000 +$14,900,000 +25% 26 Mar 2016 24 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $212,000,000 $58,100,000 +$100,000 +0.17% 26 Dec 2015 25 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $211,900,000 $61,300,000 +$8,600,000 +16% 26 Sep 2015 25 Dec 2015 10-K 26 Feb 2019 2018 FY
Q3 2015 $203,300,000 $32,700,000 +$15,300,000 +88% 27 Jun 2015 25 Sep 2015 10-K 27 Feb 2018 2017 FY
Q2 2015 $188,000,000 $59,900,000 +$17,200,000 +40% 28 Mar 2015 26 Jun 2015 10-Q 02 Aug 2016 2016 Q3
Q1 2015 $170,800,000 $58,000,000 +$16,600,000 +40% 27 Dec 2014 27 Mar 2015 10-Q 03 May 2016 2016 Q2
Q4 2014 $154,200,000 $52,700,000 +$13,700,000 +35% 27 Sep 2014 26 Dec 2014 10-Q 02 Feb 2016 2016 Q1
Q3 2014 $140,500,000 $17,400,000 -$18,100,000 -51% 28 Jun 2014 26 Sep 2014 10-K 29 Nov 2016 2016 FY
Q2 2014 $158,600,000 $42,700,000 -$2,100,000 -4.7% 29 Mar 2014 27 Jun 2014 10-Q 04 Aug 2015 2015 Q3
Q1 2014 $160,700,000 $41,400,000 +$2,200,000 +5.6% 28 Dec 2013 28 Mar 2014 10-Q 05 May 2015 2015 Q2
Q4 2013 $158,500,000 $39,000,000 +$600,000 +1.6% 28 Sep 2013 27 Dec 2013 10-Q 03 Feb 2015 2015 Q1
Q3 2013 $157,900,000 $35,500,000 29 Jun 2013 27 Sep 2013 10-K 24 Nov 2015 2015 FY
Q2 2013 $44,800,000 +$9,600,000 +27% 30 Mar 2013 28 Jun 2013 10-Q 07 Aug 2014 2014 Q3
Q1 2013 $39,200,000 29 Dec 2012 29 Mar 2013 10-Q 08 May 2014 2014 Q2
Q4 2012 $38,400,000 29 Sep 2012 28 Dec 2012 10-Q 07 Feb 2014 2014 Q1
Q2 2012 $35,200,000 31 Mar 2012 29 Jun 2012 10-Q 12 Aug 2013 2013 Q3

Keenova Therapeutics plc Annual Research and Development Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $115,700,000 30 Dec 2023 27 Dec 2024 10-K 13 Mar 2025 2024 FY
2021 $205,200,000 -$85,600,000 -29% 26 Dec 2020 31 Dec 2021 10-K 26 Mar 2024 2023 FY
2020 $290,800,000 -$58,600,000 -17% 28 Dec 2019 25 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 $349,400,000 -$11,700,000 -3.2% 29 Dec 2018 27 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $361,100,000 +$84,200,000 +30% 30 Dec 2017 28 Dec 2018 10-K 10 Mar 2021 2020 FY
2017 $276,900,000 +$15,700,000 +6% 31 Dec 2016 29 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $261,200,000 +$57,900,000 +28% 26 Sep 2015 30 Sep 2016 10-K 26 Feb 2019 2018 FY
2015 $203,300,000 +$62,800,000 +45% 27 Sep 2014 25 Sep 2015 10-K 27 Feb 2018 2017 FY
2014 $140,500,000 -$17,400,000 -11% 28 Sep 2013 26 Sep 2014 10-K 29 Nov 2016 2016 FY
2013 $157,900,000 +$13,800,000 +9.6% 29 Sep 2012 27 Sep 2013 10-K 24 Nov 2015 2015 FY
2012 $144,100,000 +$2,600,000 +1.8% 01 Oct 2011 28 Sep 2012 8-K 03 Apr 2015 2014 FY
2011 $141,500,000 25 Sep 2010 30 Sep 2011 10-K 13 Dec 2013 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.